(Enavatuzumab)Biosimilar Reference Antibody-GS40223 新品

货号：GS40223

Enavatuzumab is an investigational, humanized immunoglobulin G1 (IgG1) monoclonal antibody developed for the treatment of advanced solid tumors. It functions as a targeted agent against the TWEAK receptor (TweakR) with a dual mechanism of action. First, upon binding to TweakR on the surface of tumor cells, it can induce direct anti-proliferative and pro-apoptotic signaling within the cancer cell itself. Second, leveraging its IgG1 Fc domain, it engages the immune system to eliminate tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This combined approach aims to inhibit tumor growth both by intrinsic signaling blockade and extrinsic immune-mediated killing.